CPH.TO - Cipher Pharmaceuticals Inc Stock Price & Dividend Safety Sector: Healthcare | Exchange: Toronto Stock Exchange Current Price & Safety Score Price: 13.50 CAD StockBonds Safety Grade: Altman Z-Score (Bankruptcy Risk): 9.17 StockBond Score: -0.84 Company Description Cipher Pharmaceuticals Inc founded in 2000 and based in Oakville Canada operates as a specialized pharmaceutical enterprise The company markets a diverse portfolio of commercial therapeutic solutions These include Epuris CIPISOTRETINOIN formulated for severe acne Ozenoxacin targeting impetigo in both adult and pediatric patients Actikerall prescribed for palpable or moderately thick hyperkeratotic actinic keratosis Vaniqa a topical cream designed to mitigate unwanted facial hair growth in women BRINAVESS utilized for restoring sinus rhythm in adults and AGGRASTAT an intravenous antiplatelet medication Beyond its directly marketed offerings Ciphers portfolio encompasses various licensed products such as CIPIsotretinoin Lipofen CIPFenofibrate used in the management of hyperlipidemia a lipid metabolism disorder and ConzipDurela CIPTramadol indicated for the relief of moderate to moderately severe pain Looking to the future Cipher maintains a robust developmental pipeline which includes Trevyent a vasodilatory prostacyclin analogue aimed at treating pulmonary arterial hypertension CF101 under investigation for severe plaque psoriasis and rheumatoid arthritis MOB015 a topical terbinafine formulation for onychomycosis and DTR001 a novel cream for tattoo removal